microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This projective observational study is planned to enroll more than 300 advanced breast cancer
patients, who were proved as Her-2 positive using fluorescence in situ hybridization (FISH)
and / or immunohistochemistry, and 100 healthy donors as control. Before treatment, the
plasma microRNA will be collected and detected by microRNA extraction kit and quantitative
polymerase chain reaction (qPCR), respectively. After analyzed their microRNA expression by
microRNA predictive model, previously reported by our team, all of enrolled patients will be
classified as "probable sensitive group" or "probable resistant group". Herceptin combined
with other chemotherapy will be the backbone of salvage treatment and used for at least 3
months; the change of local masses and metastasis lesions after treatment will be documented
to evaluate the response. Based on these results, investigator aim to construct a
mathematical predictive model by analyzing the correlation of baseline microRNA expression
level and the prognosis of patients. And a diagnosis microRNA kit will be planned and
manufactured
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators:
Huiping Li,M.D., Ph.D.,Peking University Cancer Hospital Sun Yat-sen University